1-10 of 10
Susan E. Critchlow
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

Mandy Lawson, Natalie Cureton, Susana Ros, Azadeh Cheraghchi-Bashi, Jelena Urosevic, Sophie D'Arcy, Oona Delpuech, Michelle DuPont, David I. Fisher, Eric T. Gangl, Hilary Lewis, Dawn Trueman, Neha Wali, Stuart C. Williamson, Jennifer Moss, Elodie Montaudon, Heloise Derrien, Elisabetta Marangoni, Ricardo J. Miragaia, Sladjana Gagrica, Pablo Morentin-Gutierrez, Thomas A. Moss, Gareth Maglennon, Daniel Sutton, Radoslaw Polanski, Alan Rosen, Jonathan Cairns, Pei Zhang, Mònica Sánchez-Guixé, Violeta Serra, Susan E. Critchlow, James S. Scott, Justin P.O. Lindemann, Simon T. Barry, Teresa Klinowska, Christopher J. Morrow, Larissa S. Carnevalli
Journal: Cancer Research
Cancer Res (2023) 83 (23): 3989–4004.
https://doi.org/10.1158/0008-5472.CAN-23-0694
Published: 01 December 2023
View article titled, The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER<sup>+</sup> Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance
Open the PDF for The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER<sup>+</sup> Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance in another window
Includes: Supplementary data
Journal Articles

Abstract 932: Reversing PARP inhibitor resistance by targeting the replication stress response

Mark J. O'Connor, Cristina Cruz, Marta Castroviejo-Bermejo, Urszula M. Polanska, Gemma N. Jones, Anderson Wang, Zhongwu Lai, Josep Forment, Krishna Bulusu, Alba Llop-Guevara, Brian Dougherty, Cristina Saura, Rachel Brough, Chris J. Lord, Alejandra Bruna, Carlos Caldas, Stephen Fawell, J Carl Barrett, Susan E. Critchlow, Judith Balmaña, Elaine Cadogan, Violeta Serra
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 932.
https://doi.org/10.1158/1538-7445.AM2019-932
Published: 01 July 2019
View article titled, Abstract 932: Reversing PARP inhibitor resistance by targeting the replication stress response
Journal Articles

Abstract 1207: Reversing lactate-driven immunosuppression using the novel, potent and selective MCT4 inhibitor AZD0095

Susan E. Critchlow, Gareth Hughes, Anna Staniszewska, Matt King, Filippos Michopoulos, Lorna Hopcroft, Martin R. Brown, Jenna Bradley, Beverley Hammond, Pablo MorentinGutierrez, Larissa Carnevalli, Elizabeth Hardaker, Frederick W. Goldberg
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 1207.
https://doi.org/10.1158/1538-7445.AM2019-1207
Published: 01 July 2019
View article titled, Abstract 1207: Reversing lactate-driven immunosuppression using the novel, potent and selective MCT4 inhibitor AZD0095
Journal Articles

Abstract 4302: Analysis of the dose and schedule dependence of tumor kill in nonclinical tumour models after treatment with the WEE1 inhibitor AZD1775

James William Thomas Yates, Elaine Cadogan, Jennifer I. Hare, Adina M. Hughes, Urszula M. Polanska, Mark J. O'Connor, Susan E. Critchlow
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 4302.
https://doi.org/10.1158/1538-7445.AM2018-4302
Published: 01 July 2018
View article titled, Abstract 4302: Analysis of the dose and schedule dependence of tumor kill in nonclinical tumour models after treatment with the WEE1 inhibitor AZD1775
Journal Articles

Abstract 4541: Understanding the dose and schedule dependence of efficacy for the Wee1 inhibitor AZD1775 in xenograft and patient derived explant models by mathematical modelling

James W. Yates, Elaine Cadogan, Jennifer Hare, Adina Hughes, Urszula M. Polanska, Mark O'Connor, Susan E. Critchlow
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 4541.
https://doi.org/10.1158/1538-7445.AM2017-4541
Published: 01 July 2017
View article titled, Abstract 4541: Understanding the dose and schedule dependence of efficacy for the Wee1 inhibitor AZD1775 in xenograft and patient derived explant models by mathematical modelling
Journal Articles

Abstract 325: Evaluating the consequences of MCT1 inhibition in Burkitt lymphoma following treatment with AZD3965

Richard A. Noble, Natalie Bell, Helen Blair, Huw D. Thomas, Simon Bomken, Susan E. Critchlow, Stephen R. Wedge
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 325.
https://doi.org/10.1158/1538-7445.AM2016-325
Published: 15 July 2016
View article titled, Abstract 325: Evaluating the consequences of MCT1 inhibition in Burkitt lymphoma following treatment with AZD3965
Journal Articles

Abstract 3224: Pre-clinical targeting of the metabolic phenotype of lymphoma by AZD3965, a selective inhibitor of monocarboxylate transporter 1 (MCT1)

Susan E. Critchlow, Lorna Hopcroft, Lorraine Mooney, Nicola Curtis, Nicky Whalley, Haihong Zhong, Armelle Logie, Mitchell Revill, Liang Xie, Jingchuan Zhang, De-Hua Yu, Clare Murray, Paul D. Smith
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 3224.
https://doi.org/10.1158/1538-7445.AM2012-3224
Published: 15 April 2012
View article titled, Abstract 3224: Pre-clinical targeting of the metabolic phenotype of lymphoma by AZD3965, a selective inhibitor of monocarboxylate transporter 1 (MCT1)
Journal Articles

Abstract 4123: Monocarboxylate transporter 4 expression is a prognostic factor for radiotherapy outcome in squamous cell carcinoma of the head and neck

Amy L. Chadwick, Chris Womack, Gillian Watkins, Becky M. Bola, Nick Slevin, Jarrod Homer, Paul Smith, Susan E. Critchlow, Catharine M. West, Stephen R. Wedge, Ian J. Stratford
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 4123.
https://doi.org/10.1158/1538-7445.AM2011-4123
Published: 15 April 2011
View article titled, Abstract 4123: Monocarboxylate transporter 4 expression is a prognostic factor for radiotherapy outcome in squamous cell carcinoma of the head and neck
Journal Articles

Abstract 5635: Analysis of monocarboxylate transporter 4 as a biomarker shows prognostic significance as an indicator of radiotherapy in squamous cell carcinoma of the head and neck

Amy L. Chadwick, Christopher Womack, Catharine M. West, Susan E. Critchlow, Stephen R. Wedge, Ian J. Stratford
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 5635.
https://doi.org/10.1158/1538-7445.AM10-5635
Published: 15 April 2010
View article titled, Abstract 5635: Analysis of monocarboxylate transporter 4 as a biomarker shows prognostic significance as an indicator of radiotherapy in squamous cell carcinoma of the head and neck
Journal Articles

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity

Christine M. Chresta, Barry R. Davies, Ian Hickson, Tom Harding, Sabina Cosulich, Susan E. Critchlow, John P. Vincent, Rebecca Ellston, Darren Jones, Patrizia Sini, Dominic James, Zoe Howard, Phillippa Dudley, Gareth Hughes, Lisa Smith, Sharon Maguire, Marc Hummersone, Karine Malagu, Keith Menear, Richard Jenkins, Matt Jacobsen, Graeme C.M. Smith, Sylvie Guichard, Martin Pass
Journal: Cancer Research
Cancer Res (2010) 70 (1): 288–298.
https://doi.org/10.1158/0008-5472.CAN-09-1751
Published: 04 January 2010
View article titled, AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with <em>In vitro</em> and <em>In vivo</em> Antitumor Activity
Open the PDF for AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with <em>In vitro</em> and <em>In vivo</em> Antitumor Activity in another window
Includes: Supplementary data